I-Mab (IMAB) News Today $5.09 +0.38 (+8.07%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.12 +0.04 (+0.69%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is I-Mab Up Today?Toggle Visibility of Why Is I-Mab Up Today?I-Mab Sponsored ADR (NASDAQ:IMAB) shares climbed on strong analyst support and a recent earnings beat. This week, Needham & Company and HC Wainwright raised price targets and earnings forecasts across multiple years, while I-Mab topped its quarterly EPS estimates. Positive Sentiment: Needham & Company LLC raised its price objective on I-Mab from $5.00 to $6.00 and maintained a “Buy” rating. Needham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) Stock Positive Sentiment: HC Wainwright reiterated its “Buy” rating and lifted its target price on I-Mab to $7.00. I-Mab’s (IMAB) Buy Rating Reiterated at HC Wainwright Positive Sentiment: HC Wainwright raised its Q4 2025 EPS estimate for I-Mab to ($0.07) from ($0.09), underpinning its Buy rating and $7.00 price target. Free Report Positive Sentiment: HC Wainwright also lifted its Q3 2025 EPS forecast to ($0.05) from ($0.09) in the same note. Free Report Positive Sentiment: Estimates for full-year 2029 EPS were boosted by HC Wainwright to ($0.53) from ($0.81). Free Report Positive Sentiment: FY2028 EPS forecasts were raised to ($0.74) from ($1.06) by HC Wainwright. Free Report Positive Sentiment: HC Wainwright lifted its FY2027 EPS estimate to ($0.69) from ($0.97). Free Report Positive Sentiment: FY2026 EPS projections were improved to ($0.62) from ($0.87) by HC Wainwright. Free Report Positive Sentiment: HC Wainwright also boosted its FY2025 EPS estimate to ($0.23) from ($0.32). Free Report Positive Sentiment: I-Mab reported Q2 earnings of ($0.07) per share, beating the consensus of ($0.10) by $0.03. I-Mab Announces Earnings Results, Beats Estimates By $0.03 EPS Positive Sentiment: HC Wainwright’s Buy rating on I-Mab was also highlighted by American Banking & News. I-Mab’s (IMAB) "Buy" Rating Reiterated at HC Wainwright Posted 1h agoAI Generated. May Contain Errors. IMAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Needham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) StockAugust 23 at 8:13 AM | marketbeat.comI-Mab's (IMAB) Buy Rating Reiterated at HC WainwrightAugust 23 at 8:13 AM | marketbeat.comI-Mab (NASDAQ:IMAB) Announces Earnings Results, Beats Estimates By $0.03 EPSAugust 22 at 8:21 AM | marketbeat.comI-Mab's (IMAB) "Buy" Rating Reiterated at HC WainwrightAugust 22 at 2:51 AM | americanbankingnews.comI-Mab Biopharma: I-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 21 at 3:51 PM | finanznachrichten.deI-Mab to Participate in September Investor ConferencesAugust 21 at 7:00 AM | globenewswire.comI-Mab (IMAB) Expected to Announce Earnings on WednesdayAugust 21 at 2:30 AM | marketbeat.comI-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 20 at 8:04 PM | tmcnet.comI-Mab price target raised to $6 from $5 at NeedhamAugust 20 at 8:04 PM | msn.comI-Mab Reports Strong Financials and Clinical Progress in August 2025August 20 at 8:04 PM | msn.comI MAB (ADS) options imply 11.8% move in share price post-earningsAugust 19, 2025 | msn.comGround Swell Capital LLC Takes Position in I-Mab Sponsored ADR (NASDAQ:IMAB)August 17, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Trading 14.1% Higher - Here's WhyAugust 12, 2025 | marketbeat.comEverest Medicines announces strategic equity investment in I-MabAugust 1, 2025 | msn.comEverest Medicines Expands Strategic Investment in I-MABAugust 1, 2025 | prnewswire.comI-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary SharesAugust 1, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Lowered to "Hold" Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge HealthJuly 17, 2025 | globenewswire.comI-Mab to Present at the BTIG Virtual Biotechnology ConferenceJuly 14, 2025 | finance.yahoo.comI-Mab (NASDAQ:IMAB) Raised to Buy at Wall Street ZenJuly 12, 2025 | marketbeat.comI-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025July 9, 2025 | msn.comI-Mab (NASDAQ:IMAB) Given Buy Rating at HC WainwrightJuly 9, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for I-Mab (NASDAQ:IMAB)July 9, 2025 | marketbeat.comI-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - NasdaqJuly 4, 2025 | nasdaq.comI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025July 2, 2025 | globenewswire.comI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - MorningstarJuly 2, 2025 | morningstar.comMI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchJune 30, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Price Target Raised to $5.00June 27, 2025 | marketbeat.comI-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025June 26, 2025 | globenewswire.comI-Mab Biopharma: I-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 13, 2025 | finanznachrichten.deI-Mab Regains Nasdaq Compliance with Minimum Bid PriceJune 12, 2025 | tipranks.comI-Mab regains Nasdaq compliance as shares maintain $1 minimum bidJune 12, 2025 | investing.comI-Mab to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 3, 2025 | finance.yahoo.comI-Mab Advances Givastomig in Gastric Cancer with Promising Clinical DataJune 2, 2025 | tipranks.comI-Mab stock surges on Lucid Capital’s buy rating initiationMay 29, 2025 | za.investing.comI-Mab (NASDAQ:IMAB) Shares Up 5.1% - Here's What HappenedMay 29, 2025 | marketbeat.comI-Mab stock surges on Lucid Capital's buy rating initiationMay 28, 2025 | investing.comI-Mab to Present at Jefferies Global Healthcare Conference and Share New Givastomig Data at ESMO GI Cancers Congress 2025May 21, 2025 | nasdaq.comI-Mab to Present at Jefferies Global Healthcare ConferenceMay 20, 2025 | globenewswire.comI-Mab’s Financial Report Highlights Givastomig ProgressMay 16, 2025 | tipranks.comI-Mab’s Promising Clinical Developments and Financial Stability Earn ‘Buy’ Rating from AnalystMay 15, 2025 | tipranks.comI-Mab (NASDAQ:IMAB) Shares Sold by Hhlr Advisors LTD.May 1, 2025 | marketbeat.comI-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025April 30, 2025 | gurufocus.comI-Mab (NASDAQ:IMAB) Short Interest Down 64.9% in MarchApril 17, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for I-Mab (NASDAQ:IMAB) Stock PriceApril 6, 2025 | marketbeat.comI-Mab's (IMAB) Buy Rating Reiterated at Needham & Company LLCApril 6, 2025 | marketbeat.comI-Mab’s Transformative Year: Financial and Strategic HighlightsApril 4, 2025 | tipranks.comI-Mab price target lowered to $7 from $8 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comI-Mab Positions for Growth with U.S. Focus and Innovative Cancer TreatmentsApril 4, 2025 | tipranks.comI-Mab Reports Full Year 2024 Financial Results and Provides Business UpdateApril 3, 2025 | gurufocus.com Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address IMAB Media Mentions By Week IMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMAB News Sentiment▼0.750.66▲Average Medical News Sentiment IMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMAB Articles This Week▼222▲IMAB Articles Average Week Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies WAVE Life Sciences News Janux Therapeutics News Edgewise Therapeutics News Ardelyx News Harrow News ARS Pharmaceuticals News Schrodinger News Amphastar Pharmaceuticals News Vera Therapeutics News AbCellera Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMAB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.